TY - JOUR
T1 - Mathematical study of a staged-progression HIV model with imperfect vaccine
AU - Gumel, A. B.
AU - McCluskey, Connell C.
AU - Van Den Driessche, P.
N1 - Funding Information:
This work was supported in part by the Mathematics of Information Technology and Complex Systems (MITACS) and Natural Sciences and Engineering Research Council (NSERC) of Canada. The authors are grateful to Drs. C. Bowman (Institute of Biodiagnostics, Canada), E. Elbasha (Merck Inc., USA), J. Watmough (University of New Brunswick, Canada) and the anonymous reviewer for useful comments.
PY - 2006/11
Y1 - 2006/11
N2 - A staged-progression HIV model is formulated and used to investigate the potential impact of an imperfect vaccine. The vaccine is assumed to have several desirable characteristics such as protecting against infection, causing bypass of the primary infection stage, and offering a disease-altering therapeutic effect (so that the vaccine induces reversal from the full blown AIDS stage to the asymptomatic stage). The model, which incorporates HIV transmission by individuals in the AIDS stage, is rigorously analyzed to gain insight into its qualitative features. Using a comparison theorem, the model with mass action incidence is shown to have a globally-asymptotically stable disease-free equilibrium whenever a certain threshold, known as the vaccination reproduction number, is less than unity. Furthermore, the model with mass action incidence has a unique endemic equilibrium whenever this threshold exceeds unity. Using the Li-Muldowney techniques for a reduced version of the mass action model, this endemic equilibrium is shown to be globally-asymptotically stable, under certain parameter restrictions. The epidemiological implications of these results are that an imperfect vaccine can eliminate HIV in a given community if it can reduce the reproduction number to a value less than unity, but the disease will persist otherwise. Furthermore, a future HIV vaccine that induces the bypass of primary infection amongst vaccinated individuals (who become infected) would decrease HIV prevalence, whereas a vaccine with therapeutic effect could have a positive or negative effect at the community level.
AB - A staged-progression HIV model is formulated and used to investigate the potential impact of an imperfect vaccine. The vaccine is assumed to have several desirable characteristics such as protecting against infection, causing bypass of the primary infection stage, and offering a disease-altering therapeutic effect (so that the vaccine induces reversal from the full blown AIDS stage to the asymptomatic stage). The model, which incorporates HIV transmission by individuals in the AIDS stage, is rigorously analyzed to gain insight into its qualitative features. Using a comparison theorem, the model with mass action incidence is shown to have a globally-asymptotically stable disease-free equilibrium whenever a certain threshold, known as the vaccination reproduction number, is less than unity. Furthermore, the model with mass action incidence has a unique endemic equilibrium whenever this threshold exceeds unity. Using the Li-Muldowney techniques for a reduced version of the mass action model, this endemic equilibrium is shown to be globally-asymptotically stable, under certain parameter restrictions. The epidemiological implications of these results are that an imperfect vaccine can eliminate HIV in a given community if it can reduce the reproduction number to a value less than unity, but the disease will persist otherwise. Furthermore, a future HIV vaccine that induces the bypass of primary infection amongst vaccinated individuals (who become infected) would decrease HIV prevalence, whereas a vaccine with therapeutic effect could have a positive or negative effect at the community level.
KW - Global stability
KW - HIV/AIDS
KW - Staged progression
KW - Vaccination reproduction number
UR - http://www.scopus.com/inward/record.url?scp=33750693054&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750693054&partnerID=8YFLogxK
U2 - 10.1007/s11538-006-9095-7
DO - 10.1007/s11538-006-9095-7
M3 - Article
C2 - 16868850
AN - SCOPUS:33750693054
SN - 0092-8240
VL - 68
SP - 2105
EP - 2128
JO - The Bulletin of Mathematical Biophysics
JF - The Bulletin of Mathematical Biophysics
IS - 8
ER -